Platelet Aggregation Test in Clinical Hematology: Principles, Methods, and Clinical Applications

The platelet aggregation test is a cornerstone functional assay in clinical hematology that evaluates how effectively platelets clump together in response to specific chemical agonists. As the gold standard for assessing platelet function, it plays a critical role in diagnosing inherited and acquired bleeding disorders, monitoring antiplatelet drug therapy, and evaluating preoperative hemostatic risk. This article provides a comprehensive technical overview of platelet aggregation testing, including sample requirements, testing panels, methodologies, and clinical applications.

Technical Overview

The platelet aggregation test (platelet aggregometry) is a dynamic functional assay that measures the capacity of platelets to aggregate in vitro following stimulation by specific agonists such as adenosine diphosphate (ADP), collagen, epinephrine, arachidonic acid, and ristocetin. Originally developed by Born and O'Brien in 1962 using photometric turbidimetry, the test remains the international reference method for evaluating platelet function in specialized hemostasis laboratories.

The fundamental principle of light transmission aggregometry involves continuously monitoring changes in light transmittance through a stirred suspension of platelet-rich plasma (PRP). When an agonist is added, activated platelets bind fibrinogen via the GPIIb/IIIa complex, form aggregates, and the optical density of the suspension decreases. The resulting aggregation curve is characterized by several quantitative parameters:

• Maximum aggregation percentage (peak amplitude of the curve)
• Aggregation rate (maximum slope of the curve)
• Lag phase (time delay before aggregation begins)
• Aggregation pattern (monophasic, biphasic, or reversible aggregation)
• Deaggregation (spontaneous dissociation of aggregates)

Because platelet aggregation depends on intact platelet receptors, signaling pathways, fibrinogen binding, and normal coagulation factor interactions, the test provides a comprehensive functional assessment that platelet counting and morphological examination cannot offer.

Testing Samples

Specimen Collection

Venous blood is collected into tubes containing 3.2% (109 mmol/L) trisodium citrate anticoagulant at a strict 9:1 ratio of blood to anticoagulant. Proper venipuncture technique is essential, as traumatic draws may activate platelets prematurely and produce falsely reduced results. Discard tubes should be used when drawing through intravenous lines or multi-tube sampling systems.

Sample Preparation

Platelet-rich plasma (PRP) is prepared by centrifuging whole blood at low speed (approximately 150 to 200 × g for 10 to 15 minutes) at room temperature. Platelet-poor plasma (PPP) is obtained by further centrifuging the residual blood at 1,500 to 2,500 × g for 10 to 15 minutes and is used as the 100% transmission reference blank. The platelet count in PRP should ideally be adjusted to 200 to 300 × 10⁹/L, as severely thrombocytopenic samples can yield unreliable aggregation responses. For impedance-based methods, unprocessed whole blood diluted in isotonic saline may be used directly.

Pre-Analytical Requirements

• Patients should fast for 8 to 12 hours prior to collection, as lipemia interferes with optical measurement
• Antiplatelet and nonsteroidal anti-inflammatory drugs (aspirin, clopidogrel, ticagrelor, ibuprofen, dipyridamole) should be discontinued for 7 to 10 days before testing, subject to physician approval
• Alcohol, tobacco, and caffeine should be avoided for at least 12 hours before sampling
• Specimens must be tested within 2 to 4 hours of collection and maintained at 15 to 25°C
• Samples must never be refrigerated, as cold exposure activates platelets and causes irreversible aggregation
• Severely hemolyzed, clotted, or underfilled specimens should be rejected

Testing Items

A standard platelet aggregation panel includes multiple agonists, each activating platelets through distinct receptors and signal transduction pathways. Using a panel rather than a single agonist allows differentiation between various platelet function disorders based on characteristic response patterns.

• ADP: final concentrations of 2, 5, 10, or 20 μmol/L; evaluates P2Y1 and P2Y12 receptor pathways and monitors thienopyridine therapy
• Epinephrine: final concentration of 5 to 10 μmol/L; often the most sensitive indicator of mild platelet dysfunction
• Collagen: final concentration of 1 to 5 μg/mL; assesses the adhesion-mediated activation pathway and thromboxane generation
• Arachidonic acid: final concentration of 0.5 to 1.0 mmol/L; specifically evaluates the cyclooxygenase and thromboxane A2 pathway affected by aspirin
• Ristocetin: final concentrations of 1.0 to 1.5 mg/mL; induces agglutination through von Willebrand factor and the GPIb-IX-V complex
• Thrombin receptor activating peptide (TRAP): optional agonist for evaluating PAR-1 pathways and GPIIb/IIIa inhibitor monitoring

Typical reference intervals for maximum aggregation are approximately 60% to 90% for ADP, 65% to 90% for collagen, 55% to 85% for epinephrine, 60% to 90% for arachidonic acid, and 65% to 95% for ristocetin. However, laboratories must establish instrument-specific reference ranges with local healthy control populations.

Testing Methods

Light Transmission Aggregometry (LTA)

Also known as the Born method, LTA is the reference technique. PRP is incubated at 37°C in a dedicated aggregometer with continuous stirring at 1,000 to 1,200 rpm. PPP is set as the 100% transmission baseline and PRP as the 0% baseline. After agonist addition, the increase in light transmission is recorded in real time for 5 to 10 minutes. LTA offers high sensitivity for diagnosing severe platelet function disorders but requires substantial sample volume, skilled technical expertise, and strict pre-analytical control.

Impedance (Whole Blood) Aggregometry

Whole blood impedance aggregometry measures the change in electrical impedance between electrodes as platelet aggregates accumulate on their surfaces. This method requires minimal sample processing, tolerates thrombocytopenia and anemia better than LTA, and more closely reflects physiological conditions. Automated multi-channel platforms are widely used for perioperative assessment and monitoring of antiplatelet drug response.

Point-of-Care and Adjunctive Methods

Rapid cartridge-based systems perform turbidimetric or impedance aggregation assays on fingerstick or citrated venous blood, providing results within minutes for aspirin and P2Y12 inhibitor monitoring. Platelet function analyzers measuring closure time under high shear serve as screening tools, though they cannot replace aggregometry for definitive diagnosis.

Quality Control

Laboratories should run parallel normal donor controls, verify agonist potency and expiration, maintain standardized centrifugation and incubation conditions, document platelet counts, and participate in external quality assessment programs. Inter-laboratory standardization remains challenging, and result interpretation must always account for medication history and clinical context.

Applications

Platelet aggregation testing has broad diagnostic and therapeutic monitoring applications in clinical hematology:

• Diagnosis of inherited platelet function disorders: Glanzmann thrombasthenia shows absent aggregation with ADP, collagen, epinephrine, and arachidonic acid but normal ristocetin response; Bernard-Soulier syndrome shows absent ristocetin-induced agglutination with normal responses to other agonists
• Diagnosis and classification of von Willebrand disease through ristocetin-induced platelet agglutination (RIPA) and ristocetin cofactor activity testing
• Monitoring antiplatelet therapy: aspirin effect is confirmed by blunted arachidonic acid and collagen responses; clopidogrel and other P2Y12 inhibitors are assessed through attenuated ADP-induced aggregation
• Monitoring GPIIb/IIIa receptor antagonists in patients undergoing percutaneous coronary intervention
• Evaluation of acquired platelet dysfunction in uremia, chronic liver disease, myeloproliferative neoplasms, myelodysplastic syndromes, and disseminated intravascular coagulation
• Detection of drug-induced platelet inhibition caused by antibiotics, antidepressants, plasma expanders, and other agents
• Preoperative bleeding risk assessment in patients with suspicious bleeding histories
• Investigation of unexplained mucocutaneous bleeding, epistaxis, menorrhagia, and prolonged bleeding after dental or surgical procedures
• Research applications in thrombosis and hemostasis, drug development, and biomarker studies

FAQ

What is the difference between a platelet count and a platelet aggregation test? A platelet count measures the number of circulating platelets, whereas the aggregation test evaluates their functional competence. A patient can have a normal platelet count but impaired aggregation, resulting in a bleeding tendency.

How should patients prepare for the test? Patients should fast before collection, avoid antiplatelet and anti-inflammatory medications for 7 to 10 days (only with physician approval), and refrain from smoking, alcohol, and caffeine for at least 12 hours before the procedure.

What does a decreased aggregation result indicate? Reduced aggregation may reflect inherited disorders such as Glanzmann thrombasthenia or Bernard-Soulier syndrome, von Willebrand disease, medication effects, uremia, liver disease, or hematologic malignancies. Interpretation requires the full agonist panel pattern and clinical correlation.

How quickly must samples be processed? Citrated blood samples should be tested within 2 to 4 hours of collection at room temperature, since platelet function deteriorates progressively and refrigeration causes spontaneous platelet activation.

Can the test be performed on whole blood? Yes, impedance aggregometry uses whole blood directly, avoiding PRP preparation and providing faster turnaround, which is particularly valuable in urgent clinical settings such as cardiac intervention monitoring.

Why is ristocetin included in the panel? Ristocetin uniquely probes the interaction between von Willebrand factor and the platelet GPIb-IX-V receptor, enabling detection of Bernard-Soulier syndrome and von Willebrand disease, which cannot be distinguished using other agonists alone.